

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours

Information for the public

Published: 15 November 2017

www.nice.org.uk

Regorafenib (Stivarga) is available on the NHS. It is a possible treatment for unresectable or metastatic gastrointestinal stromal tumours (GIST) in adults who:

- cannot tolerate imatinib and sunitinib or have disease that has progressed after taking these drugs and
- have an Eastern Cooperative Oncology Group performance status of 0 to 1.

When assessing how having GIST affects your quality of life, healthcare professionals should take into account any disabilities or difficulties in communicating you might have.

If you are not eligible for regorafenib but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[NHS Choices](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Cancer Research UK Patient Information](#), 0808 800 4040
- [GIST Support UK](#), 0300 400 0000
- [Macmillan Cancer Support](#), 0808 808 0000
- [Sarcoma UK](#), 0207 250 8271

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2729-6